Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0309191 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS ONE, 2025. Verfasst von Kara M Calhoun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Lipopolysaccharides, Sputum, Mycobacterium Infections, Nontuberculous. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Cystic Fibrosis Foundation, National Institutes of Health.
Abstract (Originalsprache)
Background
Routine screening for nontuberculous mycobacterial (NTM) lung disease is dependent on sputum cultures. This is particularly challenging in the cystic fibrosis (CF) population due to reduced sputum production and low culture sensitivity. Biomarkers of infection that do not rely on sputum may lead to earlier diagnosis, but validation trials require a unique prospective design.
Purpose
The rationale of this trial is to investigate the utility of urine lipoarabinomannan (LAM) as a test to identify people with CF with a new positive NTM culture. We hypothesize that urine LAM is a sensitive, non-invasive screening test with a high negative predictive value to identify individuals with a relatively low risk of having positive NTM sputum culture. Study design This is a prospective, single-center, non-randomized observational study in adults with CF, 3 years of negative NTM cultures, and no known history of NTM positive cultures. Patients are followed for two year-long observational periods with the primary endpoint being a positive NTM sputum culture within a year of a positive urine LAM result and a secondary endpoint of a positive NTM sputum culture within 3 years of a positive urine LAM result. Study implementation includes remote consent and sample collection to accommodate changes from the COVID-19 pandemic.
Conclusions
This report describes the study design of an observational study aimed at using a urine biomarker to assist in the diagnosis of NTM lung infection in pwCF. If successful, urine LAM could be used as an adjunct to traditional sputum cultures for routine NTM screening, and replace cultures in low-risk individuals unable to produce sputum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Department of Medicine, National Jewish Health, Denver, Colorado, USA.
- Center for Genes, Environment, and Health, National Jewish Health, Denver, Colorado, USA.
- Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
ORCID-Profile: Katie Poch, Kenneth C Malcolm
Förderung
- NHLBI NIH HHS
- Cystic Fibrosis Foundation
- National Institutes of Health
Zitieren
APA
Calhoun, K. M., Armantrout, E., Poch, K., Caceres, S., Lovell, V. K., Jones, M., Malcolm, K. C., Vestal, B., Wheeler, E., Rysavy, N., Manzer, J., Aboellail, I., Chatterjee, D., & Nick, J. A. (2025). Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis. PLOS ONE. https://doi.org/10.1371/journal.pone.0309191
Vancouver
Calhoun KM, Armantrout E, Poch K, Caceres S, Lovell VK, Jones M, et al. Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis. PLOS ONE. 2025. doi:10.1371/journal.pone.0309191
BibTeX
@article{Calhoun2025,
author = {Calhoun, Kara M and Armantrout, Emily and Poch, Katie and Caceres, Silvia and Lovell, Valerie K and Jones, Marion and Malcolm, Kenneth C and Vestal, Brian and Wheeler, Emily and Rysavy, Noel and Manzer, Jordan and Aboellail, Ibrahim and Chatterjee, Delphi and Nick, Jerry A},
title = {Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0309191}
}
EUVIMED